Early research (Phase 1)UnknownNCT03015922What this trial is testingViral Immunotherapy in Relapsed/Refractory Multiple MyelomaWho this might be right forMultiple Myeloma University of Leeds 4
Not applicableStudy completedNCT00521430What this trial is testingDonor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other DiseaseWho this might be right forLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more Asan Medical Center 30
Early research (Phase 1)Study completedNCT00161187What this trial is testingIrradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid TumorWho this might be right forCancer University of Medicine and Dentistry of New Jersey 37
Not applicableStudy completedNCT02976493What this trial is testingElotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Bristol-Myers Squibb 500
Testing effectiveness (Phase 2)WithdrawnNCT01652014What this trial is testingSingle or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAdult Acute Lymphoblastic Leukemia in Remission+51 more University of Medicine and Dentistry of New Jersey
Early research (Phase 1)Ended earlyNCT04045028What this trial is testingEvaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWho this might be right forMultiple MyelomaNon-Hodgkin LymphomaB-Cell Lymphoma Genentech, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT02159365What this trial is testingStudy of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsWho this might be right forMultiple Myeloma Bristol-Myers Squibb 84
Not applicableNot Yet RecruitingNCT07015021What this trial is testingThe Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM PatientsWho this might be right forMultiple MyelomaCarfilzomibDaratumumab+1 more The First Affiliated Hospital of Soochow University 72
Testing effectiveness (Phase 2)Study completedNCT02963493What this trial is testingMelphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma Oncopeptides AB 157
Early research (Phase 1)Study completedNCT00858234What this trial is testingPhase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)Who this might be right forMultiple Myeloma Merck Sharp & Dohme LLC 9
Early research (Phase 1)Study completedNCT01164709What this trial is testingNelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic CancerWho this might be right forLeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more Swiss Cancer Institute 18
Early research (Phase 1)Study completedNCT00060372What this trial is testingIpilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerWho this might be right forAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+59 more National Cancer Institute (NCI) 21
Not applicableEnded earlyNCT00726830What this trial is testingMethadone, Morphine, or Oxycodone in Treating Pain in Patients With CancerWho this might be right forBrain and Central Nervous System TumorsChronic Myeloproliferative DisordersLeukemia+8 more M.D. Anderson Cancer Center 1
Large-scale testing (Phase 3)UnknownNCT00747877What this trial is testingHigh-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After ChemotherapyWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Leeds Cancer Centre at St. James's University Hospital 460
Early research (Phase 1)Study completedNCT01129193What this trial is testingAR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaWho this might be right forAdult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell Lymphoma+64 more Amir Mortazavi 44
Early research (Phase 1)Looking for participantsNCT06375044What this trial is testingStudy of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Jiangsu Simcere Pharmaceutical Co., Ltd. 130
Early research (Phase 1)Looking for participantsNCT06604715What this trial is testingJNJ-87562761 in Participants With Relapsed or Refractory Multiple MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Janssen Research & Development, LLC 80
Testing effectiveness (Phase 2)Study completedNCT00530816What this trial is testingPhase 2 Study of Carfilzomib in Relapsed Multiple MyelomaWho this might be right forMultiple Myeloma Amgen 164
Testing effectiveness (Phase 2)Study completedNCT00908232What this trial is testingTreatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDWho this might be right forMultiple Myeloma Janssen-Cilag International NV 163
Testing effectiveness (Phase 2)Study completedNCT01866293What this trial is testingCabozantinib (XL184) in Patients With Relapsed or Refractory MyelomaWho this might be right forRelapsed or Refractory Multiple Myeloma Memorial Sloan Kettering Cancer Center 11